Market revenue in 2021 | USD 212.3 million |
Market revenue in 2030 | USD 1,319.1 million |
Growth rate | 22.5% (CAGR from 2021 to 2030) |
Largest segment | Serum biomarkers |
Fastest growing segment | Hepatic Fibrosis Biomarkers |
Historical data covered | 2018 - 2020 |
Base year for estimation | 2021 |
Forecast period covered | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers |
Key market players worldwide | Genfit SA, Siemens AG, Quest Diagnostics Inc, AstraZeneca PLC, Meridian Bioscience, Labcorp Holdings Inc, Pfizer Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis biomarkers market will help companies and investors design strategic landscapes.
Serum biomarkers was the largest segment with a revenue share of 32.83% in 2021. Horizon Databook has segmented the Europe non-alcoholic steatohepatitis biomarkers market based on serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
Europe was estimated to be the second-largest market due to the presence of prominent research institutes and market players operating in this region. Market growth can be attributed to increasing collaborations between European universities and biomarker solution providers.
Moreover, the European Alliance of Medical Research Infrastructures (AMRI) makes strategies and helps improve the research process related to diagnostics tests & biomarker development. Several initiatives undertaken by government and private organizations to fund R&D pertaining to biomarkers and create awareness about the benefits of biomarkers are expected to boost the market.
Major factors responsible for NASH are diabetes and obesity. This depicts the high untapped opportunity for companies to improve sales in the European region by increasing awareness related to prognostic usage of biomarkers by patients with underlying conditions.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe non-alcoholic steatohepatitis biomarkers market , including forecasts for subscribers. This continent databook contains high-level insights into Europe non-alcoholic steatohepatitis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account